Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Drawing on the film Wonder, this article examines how a narrative of community acceptance offers sustaining relationships for people with unusual facial appearance.
AMA J Ethics. 2019;21(11):E1003-1008. doi:
10.1001/amajethics.2019.1003.
Efforts to meet the demand for organs have long had disproportionate effects on members of particular races, not only because of disparate levels of need for transplants but because of the way our donation system works.
Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported.
AMA J Ethics. 2019;21(11):E968-973. doi:
10.1001/amajethics.2019.968.